Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) FCF Margin (2020 - 2025)

Historic FCF Margin for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to 1349.62%.

  • TScan Therapeutics' FCF Margin rose 14423700.0% to 1349.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 1612.88%, marking a year-over-year decrease of 4317000.0%. This contributed to the annual value of 4071.27% for FY2024, which is 37648200.0% down from last year.
  • As of Q3 2025, TScan Therapeutics' FCF Margin stood at 1349.62%, which was up 14423700.0% from 1123.08% recorded in Q2 2025.
  • TScan Therapeutics' FCF Margin's 5-year high stood at 169.75% during Q3 2023, with a 5-year trough of 5295.41% in Q1 2024.
  • Over the past 5 years, TScan Therapeutics' median FCF Margin value was 637.2% (recorded in 2021), while the average stood at 1444.42%.
  • As far as peak fluctuations go, TScan Therapeutics' FCF Margin crashed by -48742900bps in 2024, and later surged by 39304600bps in 2025.
  • Quarter analysis of 5 years shows TScan Therapeutics' FCF Margin stood at 581.32% in 2021, then grew by 3bps to 561.78% in 2022, then soared by 40bps to 336.08% in 2023, then plummeted by -1166bps to 4255.64% in 2024, then soared by 68bps to 1349.62% in 2025.
  • Its FCF Margin stands at 1349.62% for Q3 2025, versus 1123.08% for Q2 2025 and 1801.84% for Q1 2025.